Skip to main content
. 2022 Jan 1;107(1):19–34. doi: 10.3324/haematol.2021.278717

Figure 3.

Figure 3.

Schema for treatment choice at the time of first disease progression. After ruling out histological transformation, the choice of agent depends on prior therapy, the timing of relapse, tumor burden, and patients’ ability to tolerate therapy. R: rituximab; O: obinutuzumab; CHOP: cyclophosphamide, adriamycin, vincristine, prednisone; CVP: cyclophosphamide, vincristine, prednisone: ASCT: autologous stem cell transplantation.